Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Akero Therapeutics, Inc. AKRO NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
37/100
1/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$46.00
-15.8%

Akero Therapeutics, Inc. (AKRO) is a Biotechnology company in the Healthcare sector, currently trading at $54.65. It has a SharesGrow Score of 36/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Analyst consensus target is AKRO = $46 (-15.8% upside).

Net income is $252M (loss), growing at -37.9%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $36M against $750M equity (Debt-to-Equity (D/E) ratio 0.05, conservative). Current ratio is 19.38 (strong liquidity). Debt-to-assets is 4.4%. Total assets: $826M.

Analyst outlook: 10 / 14 analysts rate AKRO as buy (71%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 20/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 40/100 (Fail), Future 49/100 (Partial), Income ?/100 (Fail).

$46.00
▼ 15.83% Downside
Average Price Target
Based on 14 Wall Street analysts offering 12-month price targets for Akero Therapeutics, Inc., the average price target is $46.00, with a high forecast of $56.00, and a low forecast of $38.00.
Highest Price Target
$56.00
Average Price Target
$46.00
Lowest Price Target
$38.00

AKRO SharesGrow Score Overview

45/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 20/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 40/100
Gross margin is + market cap
FUTURE 49/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — AKRO

✗
VALUE Fail
20/100
AKRO trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $46, implying -15.8% from the current price $55. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
AKRO: +0%/yr revenue is, -37.9%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet AKRO: Debt-to-Equity (D/E) ratio 0.05 (conservative), Current ratio is 19.38 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
40/100
AKRO: Gross margin is 0% (+0 pp trend), $4B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
49/100
Analyst outlook: 10 / 14 analysts rate AKRO as buy (71%). Analyst consensus target is $46 (-15.8% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range21.34-58.4
Volume11.61M
Avg Volume (30D)2.56M
Market Cap$4.5B
Beta (1Y)-0.40
Share Statistics
EPS (TTM)-3.75
Shares Outstanding$67.14M
IPO Date2019-06-20
Employees69
CEOAndrew Cheng
Financial Highlights & Ratios
EBITDA$-285.42M
Net Income$-252.06M
Operating Income$-285.42M
Total Cash$743.08M
Total Debt$36.46M
Net Debt$-303.78M
Total Assets$825.89M
Price / Earnings (P/E)-14.6
Analyst Forecast
1Y Price Target$45.00
Target High$56.00
Target Low$38.00
Upside-17.7%
Rating ConsensusBuy
Analysts Covering14
Buy 71% Hold 29% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS00973Y1082

Price Chart

Track all markets on TradingView
AKRO
Akero Therapeutics, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
21.34 52WK RANGE 58.40

People Also View

RVMD
RVMD
Revolution Medicines, Inc.
$147.01
+7.86%
 MDGL
MDGL
Madrigal Pharmaceuticals, Inc.
$524.99
-0.13%
 PTGX
PTGX
Protagonist Therapeutics, Inc.
$104.72
+7.33%
 RETA
RETA
Reata Pharmaceuticals, Inc.
$172.36
+0.02%
 TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
 VKTX
VKTX
Viking Therapeutics, Inc.
$35.52
+1.46%
 STOK
STOK
Stoke Therapeutics, Inc.
$35.86
+2.31%
 ICPT
ICPT
Intercept Pharmaceuticals, Inc.
$19.00
+0.21%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message